Shandong Suncadia Medicine Co., Ltd.
Quick facts
Marketed products
- Everolimus Tablets · Oncology; Immunology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
Phase 3 pipeline
- Fulvestrant injection ;Dalpiciclib Isethionate · Oncology
This combination uses fulvestrant to block estrogen receptors in breast cancer cells while dalpiciclib inhibits cyclin-dependent kinases 4 and 6 to prevent cell cycle progression. - HRS-1780 Tablets
HRS-1780 is an investigational small molecule with unknown mechanism of action in Phase 3 development. - HRS-1893 Tablets
HRS-1893 is an investigational small molecule with unknown mechanism of action in Phase 3 development. - HRS-7535 tablet
HRS-7535 tablet's mechanism of action is not publicly available. - HRS-7535 Tablets
HRS-7535 is an investigational small molecule with unknown mechanism of action in Phase 3 development. - HRS-8080 Tablet ; Dalpiciclib Isethionate · Oncology
Dalpiciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression by preventing phosphorylation of the retinoblastoma protein. - HRS-8080 Tablets
HRS-8080 is an investigational small molecule with unknown mechanism of action in Phase 3 development. - Tamoxifen Citrate Tablets · Oncology
Tamoxifen Citrate Tablets work by competitively inhibiting estrogen receptors on tumor cells.
Phase 2 pipeline
- HRS-1301 Tablet
- HRS-1893
- HRS-2129 Tablets
- HRS-5346 · Diabetes
HRS-5346 is a small molecule that targets the SGLT2 receptor. - HRS-7058
- HRS-7085
- Tramadol Hydrochloride SR Tablets
Phase 1 pipeline
- [14C]HRS-7535
- [14C]HRS-8080
- Fluvustat · Other
- HR20031 FDC
- HR20033 tablets
- HRS-1301 Tablets
- HRS-1780
- HRS-1893 tablet A
- HRS-1893 tablet B
- HRS-2129
- HRS-2189 Tablets
- HRS-3802
- HRS-5346 tablets
- HRS-6208
- HRS-6209
- HRS-6719
- HRS-7085 simulant
- HRS-7535（C）Tablets
- HRS-7535（D）Tablets
- HRS-7535 Tables
- HRS-8080; Dalpiciclib Isethionate Tablets
- HRS-8080; SHR-A1811
- HRS-8080; SHR-A2009
- hrx0701 tablets
- Omeprazole Enteric-coated Capsules
- Reference formulation of HRS-1893 tablet
- SHR-A2009; SHR-1316
- Test formulation of HRS-1893 tablet
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Shandong Suncadia Medicine Co., Ltd. portfolio CI brief
- Shandong Suncadia Medicine Co., Ltd. pipeline updates RSS
Frequently asked questions about Shandong Suncadia Medicine Co., Ltd.
What are Shandong Suncadia Medicine Co., Ltd.'s marketed drugs?
Top marketed products include Everolimus Tablets.
What is Shandong Suncadia Medicine Co., Ltd.'s pipeline?
Shandong Suncadia Medicine Co., Ltd. has 8 drugs in Phase 3, 7 in Phase 2, 28 in Phase 1. Late-stage candidates include Fulvestrant injection ;Dalpiciclib Isethionate, HRS-1780 Tablets, HRS-1893 Tablets, HRS-7535 tablet.
Related
- Everolimus Tablets · Oncology; Immunology
- Sector hub: All tracked pharma companies